KNTV NBC Nightly News With Lester Holt February 8, 2019 01:42:00
Known as 3,4-dap was inexpensive to make. given to patients free of charge by a small drug company, jacobus. but jacobus has been blocked by another company, catalyst pharmaceuticals, who conducted clinical trials and got fda approval for a slightly modified version. they can sell it exclusively for seven years, under a law designed to encourage drugs for rare disease. catalyst set their average price for the drug at $375,000 a year. >> this was not innovative. this was not good medicine. this was good lawyering. >> reporter: the shullers' insurance will cover the cost. in will's case, $500,00...